Tag: ArQule

Finance

Biotech New Lows: ArQule (NASDAQ:ARQL), OvaScience Inc (NASDAQ:OVAS), Uniqure (NASDAQ:QURE), Egalet Corp (NASDAQ:EGLT)

ArQule Inc. (NASDAQ:ARQL) announced that the Company will present at the Needham 13th Annual Healthcare Conference. The presentation will be web cast and may be accessed through the investor relations section of the Company’s website http://www.arqule.com. ArQule, Inc. (NASDAQ:ARQL) stock performance was -2.92% in last session and finished the day at $1.66. Traded volume was 530,559.00million shares in the last session and the average volume … Continue reading Biotech New Lows: ArQule (NASDAQ:ARQL), OvaScience Inc (NASDAQ:OVAS), Uniqure (NASDAQ:QURE), Egalet Corp (NASDAQ:EGLT)

Colin Pettis
Finance

New Lows: ArQule, Inc. (NASDAQ:ARQL), AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO), Tetralogic Pharmaceuticals Corp (NASDAQ:TLOG), TrovaGene Inc (NASDAQ:TROV)

ArQule, Inc (NASDAQ:ARQL) CEO Paolo Pucci purchased 5,000 shares of the company’s stock in a transaction dated Tuesday, May 20th. The stock was purchased at an average cost of $1.42 per share, with a total value of $7,100.00. Following the transaction, the chief executive officer now directly owns 232,280 shares of the company’s stock, valued at approximately $329,838. ArQule, Inc. (NASDAQ:ARQL) stock performance was -2.76% … Continue reading New Lows: ArQule, Inc. (NASDAQ:ARQL), AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO), Tetralogic Pharmaceuticals Corp (NASDAQ:TLOG), TrovaGene Inc (NASDAQ:TROV)

Mark Doerr